Publications by authors named "Alienor Campredon"
Objectives: Lumacaftor-ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) modulator known to improve clinical status in people with cystic fibrosis (CF). The aim of this study was to assess lung structural changes after 1 year of lumacaftor-ivacaftor treatment and to use unsupervised machine learning to identify morphological phenotypes of lung disease that are associated with response to lumacaftor-ivacaftor.
Methods: Adolescents and adults with CF from a French multicentre real-world prospective observational study evaluating the first year of treatment with lumacaftor-ivacaftor were included if they had pre-therapeutic and follow-up chest computed tomography (CT) scans available.
Article Synopsis
- COVID-19, which surfaced in 2019, spread quickly around the globe, and CT imaging is crucial for screening, quantifying, and staging the disease.
- Effective staging is necessary for healthcare management, such as planning for ICU beds and enhancing drug development through quick assessments.
- This study explored the use of medical imaging and AI to improve disease quantification and patient outcomes, demonstrating promising results through automated deep learning methods and combining imaging data with clinical information.